Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
August 27, 2020 12:38 ET
|
Onxeo SA
PARIS, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Transfer of the Listing of Onxeo Securities From the Euronext Paris Regulated Market (Compartment C) to the Euronext Growth Paris Multilateral Trading Facility
July 29, 2020 12:30 ET
|
Onxeo SA
PARIS, July 29, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties
June 25, 2020 07:00 ET
|
Onxeo SA
PARIS, June 25, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020
June 22, 2020 07:00 ET
|
Onxeo SA
PARIS, June 22, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo Announces Approval of the REVocan Study by Regulatory Authorities
May 29, 2020 01:30 ET
|
Onxeo SA
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer The first treatments could begin in the next few weeks, with the...
Bryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” Recommendation
May 27, 2020 08:00 ET
|
Onxeo SA
PARIS, May 27, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi
May 19, 2020 12:00 ET
|
Onxeo SA
PARIS, May 19, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update
April 17, 2020 12:24 ET
|
Onxeo SA
Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended financial visibility into Q2 2021AsiDNA™ to advance to phase 1b/2...
Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC
April 06, 2020 12:30 ET
|
Onxeo SA
This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology$6.6m received from Acrotech extends Onxeo’s cash runway into Q2...
Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020
February 27, 2020 11:45 ET
|
Onxeo SA
PARIS, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...